Schedule of Deferred tax assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 121,804	$ 109,544
Research and development tax credit carryforwards	5,674	5,674
Stock-based compensation expense	17,717	16,539
Startup costs	431	498
Intangible assets	3,028	3,442
Deferred revenue	1,469	1,441
Unicap	5	5
Imputed interest on contingent payments	97	110
Legal fee capitalization and amortization	1,053	1,171
Capitalized research and development	22,903	26,613
IRC Section 163j interest	1,471
Other	5,755	4,751
Total deferred tax assets	181,407	169,788
Valuation allowance	(181,416)	(169,797)
Net deferred tax liabilities	$ (9)	$ (9)